Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Characterization of molecular and cellular functions of the cyclin‐dependent kinase CDK9 using a novel specific inhibitor

8 Oct 2013

Abstract excerpt

BACKGROUND AND PURPOSE: The cyclin-dependent kinase CDK9 is an important therapeutic target but currently available inhibitors exhibit low specificity and/or narrow therapeutic windows. Here we have used a new highly specific CDK9 inhibitor, LDC000067 to interrogate gene control mechanisms mediated by CDK9. EXPERIMENTAL APPROACH: The selectivity of LDC000067 was established in functional kinase assays. Functions...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Advanced Breast Cancer Therapies
Share to Cancer-related Molecular Pathways
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 24102143
DOI: 10.1111/bph.12408

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Characterization of molecular and cellular functions of the cyclin‐dependent kinase CDK9 using a novel specific inhibitorPMID 24102143Read ↗

Addressing Transcriptional Dysregulation in Cancer through CDK9 InhibitionSemantic proximity Read ↗

CDK9: A Comprehensive Review of Its Biology, and Its Role as a Potential Target for Anti-Cancer AgentsSemantic proximity Read ↗

CDK9 as an Appealing Target for Therapeutic InterventionsSemantic proximity Read ↗

CDK9: A key player in cancer and other diseasesSemantic proximity Read ↗

Deregulations in the Cyclin-Dependent Kinase-9-Related Pathway in Cancer: Implications for Drug Discovery and DevelopmentSemantic proximity Read ↗

CDK7 Inhibitors in Cancer Therapy: The Sweet Smell of Success?Semantic proximity Read ↗

Targeting CDK9 for Anti-Cancer TherapeuticsSemantic proximity Read ↗

Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancerSemantic proximity Read ↗

CDK9 inhibition induces epigenetic reprogramming revealing strategies to circumvent resistance in lymphomaSemantic proximity Read ↗

Systematic Kinase Inhibitor Profiling Identifies CDK9 as a Synthetic Lethal Target in NUT Midline CarcinomaSemantic proximity Read ↗

CDK7 inhibitors as anticancer drugsSemantic proximity Read ↗

Perspective of Cyclin-dependent kinase 9 (CDK9) as a Drug TargetSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.